8 October 2014
ValiRx Plc
('ValiRx' or the 'Company')
Early Completion of Equity Swap Agreement between YA Global Master SPV. Ltd. ("Yorkville") and ValiRx Plc dated 24 December 2013
ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine announces that the equity swap Agreement with YA Global Masters SPV Ltd ("Yorkville"), details of which were announced on 27 December 2013, has been exercised in full by agreement between the parties.
"Yorkville" has committed to sell 206,500,000 of its ordinary shares in the Company through ValiRx's broker Daniel Stewart & Company Plc. This has now been completed and Yorkville is fulfilling its outstanding commitment under the terms of the Agreement to the Company.
Yorkville retains an interest over 86,662,392 ValiRx shares which are held outside the terms of the Swap agreement.
ValiRx's CEO, Satu Vainikka, said "We appreciate Yorkville's flexibility and support to the Company over the last year with respect to the management of working capital during this exciting period in ValiRx's development."
- ENDS -
For more information, please contact:
ValiRx Plc Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka www.ValiRx.com
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc (Broker) Tel: +44 (0) 20 7776 6550
Mark Treharne
Peckwater PR Tel: +44 (0) 7879 458 364
Tarquin Edwards [email protected]
